Genome Corp. Announces Formation of Scientific Advisory Board and Additional Seed Funding

Providence, R.I., January 22, 2008 — Six-month-old Genome Corp. today announced the founding members of its scientific advisory board, and an additional $250,000 in funding from the Slater Technology Fund. The three founding members of the advisory board include:

Prof. Norman J. Dovichi, Ph.D. is the endowed professor of analytical chemistry at the University of Washington. Dr. Dovichi started the quest for single fluorophore detection while a postdoctoral fellow with the National Flow Cytometry Resource (NFCR) at Los Alamos National Laboratory in the early 1980s, and subsequently developed sheath flow detection for capillary electrophoresis while at the University of Alberta. This was one of the key technologies behind the ABI 3700 that was used to sequence the human reference genomes, for which Dr. Dovichi was recognized as one of the ¡°Unsung Heroes¡± of the Human Genome Project.

Prof. Annelise E. Barron, Ph.D. is associate professor of bioengineering at Stanford University. Dr. Barron is a polymer chemist who has developed many state-of-the-art sieving matrices for Sanger sequencing, including her just published work on ¡°Ultrafast DNA sequencing on a microchip by a hybrid separation mechanism that gives 600 bases in 6.5 minutes¡± in the Proceedings of the National Academy of Sciences with her graduate student, Christopher Fredlake, at her former institution, Northwestern University. She has also published work on extremely long read length separations ¡Ý1,300 bases.

Prof. Patrick S. Doyle, Ph.D. is an associate professor of chemical engineering at MIT. Prof. Doyle¡¯s research group is involved in studies of the dynamics of biopolymers and complex fluids, including theoretical and empirical studies of DNA migration during electrophoresis.

¡°We have assembled a truly unique group of advisors to help guide the further development of our massively parallel Sanger sequencing technology,¡± states Dr. Ulmer. ¡°They have all worked together previously and have individually made significant contributions to the advancement of gel electrophoresis. We look to the synergy they will provide us going forward. Of most recent note, Annelise¡¯s recently-published results provide further dramatic evidence for the future potential of Sanger sequencing to achieve the $1,000 Genome.¡±

In addition, the company announced a second round of investment by the Slater Technology Fund of Rhode Island, bringing Slater¡¯s aggregate investment to date to $500,000. Richard G. Horan, senior managing director of the Slater Fund, stated: ¡°A world-class advisory board such as that coming together under Dr. Ulmer¡¯s leadership will greatly accelerate Genome Corp.¡¯s ability to advance its sequencing technology into commercialization. With the broad embrace of Sanger sequencing technology among genome researchers worldwide, we envision very rapid market penetration when implemented at scale.¡±

About Genome Corp.
Genome Corporation is a privately held, development-stage genomics company located in Providence, Rhode Island. The company aims to become the dominant global provider of DNA sequence information to life scientists, clinicians and individuals based on a proprietary and massively parallel implementation of Sanger sequencing. The company plans to build the world¡¯s largest DNA sequencing ¡°factory,¡± combining the best available technologies in an innovative and unprecedented manner to achieve an economy of scale and cost of sequencing unmatched elsewhere. As the low cost provider of sequence data, the venture hopes to effect a paradigm shift in commercial sequencing, thereby rapidly penetrating this multi-billion dollar information service opportunity.

About Slater Technology Fund
The Slater Technology Fund is a state-backed venture capital fund that invests in new companies committed to basing and building their businesses in Rhode Island. Slater focuses its resources on the support of entrepreneurs who have the vision, leadership and commitment to build substantial commercial enterprises. Slater typically invests at the inception stage in the development of a new venture, often based upon ideas and technologies originating in academic institutions and/or government research laboratories located within the region. In most cases, investments are premised upon the possibility of raising substantial follow-on financing, from venture capital investors or from strategic partners, with a view toward accelerating the generation of significant numbers of high-value, high-wage jobs over the intermediate to longer-term. For more information, visit www.slaterfund.com.

For More Information
Laura Nelson or Kaycee Roberts
SVM Public Relations
(401) 490-9700
laura.nelson@svmpr.com
kaycee.roberts@svmpr.com